Cancer

Title
A Blind, Randomized Study of Fidaxomicin or Placebo for Prevention of C-diff Infection That Can Cause Diarrhea in Adults Undergoing Stem Cell Transplantation
Trial Number
204809112112
Number of Participants
600
Principal Investigator

Patrick Stiff

M.D.
Hematology/Oncology
Coleman Professor of Oncology
Category
Cancer
Eligibility

Male or female 18 years of age or older; individuals undergoing HSCT with fluoroquinolone prophylaxis.

Purpose

The purpose of this research is to find out if fidaxomicin is safe and effective in the prevention of Clostridium-difficile associated diarrhea for people that will have a hematopoietic stem cell transplantation. The use of fidaxomicin to prevent C-diff diarrhea is considered experimental. In this research fidaxomicin will be compared with a placebo (an inactive substance).

Enrollment

(708) 327-2241

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.